Please select the option that best describes you:
Would you consider using daratumumab in the first line setting for non-transplant eligible multiple myeloma?
To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Daratumumab. We already know that maintenance therapy prolongs PFS according to past studies which gives the experimental arm and unfair advantage over the control arm.
Answer from: Medical Oncologist at Academic Institution
Let's wait for the MAIA data to come out, but Dara will likely be moving in for the TI MM folks in combos that are more relevant for the US practice soon.
Answer from: Medical Oncologist at Community Practice
I would, the Dara combination for the recurrent populations are outstanding and there is no reason added to VRD it should not improve the outcomes
The MRD- rate in these studies are very impressive, and it appears that MRD- at less than 1 in a million equals to a high proportion of conti...
Answer from: Medical Oncologist at Academic Institution
I will be careful to identify those who are ineligible for transplant. Regarding the ALCYONE trial (daratumumab/melphalan/bortezomib/prednisone) is not applicable in the USA because we rarely use PO melphalan upfront. My number 1 option to treat this group of pts is VRD per the SWOG S0777, as it sho...
Answer from: Medical Oncologist at Community Practice
My biggest challenge here after identifying that the person is not transplant eligible is identifying who should be on doublet vs triplet! As for a clear reason the patient was not transplant eligible. In another world what is the scenario where you will use only rd?
Thank you for your quick reply! Definitely an imp...